Anifrolumab for Primary Antiphospholipid Syndrome
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18–70 years old and weigh at least 40 kg
- Have primary antiphospholipid syndrome confirmed by blood tests and clinical signs (such as blood clots, low platelets, or kidney/heart involvement)
- Not be pregnant, planning pregnancy, or breastfeeding; use effective contraception if applicable
- Not have active tuberculosis or untreated latent TB; negative TB test required
- No recent serious infections, HIV, hepatitis B or C, or certain herpes infections
- Not currently taking certain immune-suppressing drugs or biologics (must stop 90 days before starting)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if belimumab lowers harmful antibody levels in people with antiphospholipid syndrome (APS), a condition that increases blood clot risk. It may help those who are already on a stable APS treatment plan.
This trial tests if a new drug called anifrolumab can help treat lupus in people who haven't taken strong medications like biologics or immunosuppressants before. It looks at overall disease activity and the chance to reduce steroid use.
This study tests whether anifrolumab, a drug that targets the immune system, can improve markers of blood vessel health in people with lupus. It may help reduce the risk of heart problems associated with lupus.
This trial tests anifrolumab, an investigational drug that may help reduce lupus activity in people with moderate-to-severe disease. If you have active lupus despite current treatments, this study might offer a new option.
This study tests an experimental drug called anifrolumab, which is given as an injection or infusion, to see how it works in people with active lupus. It may help reduce lupus symptoms by targeting the immune system.
This study looks at potential risks of the lupus medication anifrolumab in people with moderate to severe SLE. It focuses on serious infections and malignancies to see how safe the treatment is.
Hear when a new Antiphospholipid Syndrome (APS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.